15种抗菌剂对南非肠球菌临床分离株的体外活性
In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.
作者信息
Struwig M C, Botha P L, Chalkley L J
机构信息
Department of Medical Microbiology, University of the Orange Free State, Bloemfontein 9300, South Africa.
出版信息
Antimicrob Agents Chemother. 1998 Oct;42(10):2752-5. doi: 10.1128/AAC.42.10.2752.
Abstract
The activities of a panel of currently available antibiotics and the investigational agents LY 333328, linezolid, CL 331,002, CL 329,998, moxifloxacin (BAY 12-8039), trovafloxacin, and quinupristin-dalfopristin against 274 clinical isolates of enterococci were determined. No vancomycin resistance or beta-lactamase production was observed. Except for 12 isolates (all non-Enterococcus faecalis) showing reduced susceptibility to quinupristin-dalfopristin (MIC, >/=4 microg/ml), the new agents exhibited promising in vitro antienterococcal activity.
摘要
测定了一组目前可用抗生素以及研究用药物LY 333328、利奈唑胺、CL 331002、CL 329998、莫西沙星（BAY 12 - 8039）、曲伐沙星和奎奴普丁-达福普丁对274株肠球菌临床分离株的活性。未观察到万古霉素耐药或β-内酰胺酶产生。除12株分离株（均为非粪肠球菌）对奎奴普丁-达福普丁敏感性降低（MIC，≥4μg/ml）外，这些新药在体外表现出有前景的抗肠球菌活性。
相似文献
1
In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.15种抗菌剂对南非肠球菌临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Oct;42(10):2752-5. doi: 10.1128/AAC.42.10.2752.
2
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
3
Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).韩国临床分离株中莫匹罗星、达托霉素、利奈唑胺、奎奴普丁/达福普汀和替加环素对耐万古霉素肠球菌（VRE）的抗菌活性（1998年和2005年）
J Biochem Mol Biol. 2007 Nov 30;40(6):881-7. doi: 10.5483/bmbrep.2007.40.6.881.
4
Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.欧洲引起感染的肠球菌的抗菌药敏模式。欧洲耐万古霉素肠球菌研究小组。
Antimicrob Agents Chemother. 1999 Oct;43(10):2542-6. doi: 10.1128/AAC.43.10.2542.
5
[Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].[耐万古霉素肠球菌：奎奴普丁/达福普汀（RP 59500）的体外活性]
Enferm Infecc Microbiol Clin. 1999 Aug-Sep;17(7):335-9.
6
Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.采用不同最低抑菌浓度（MIC）折点系统评估瑞典重症监护病房中肠球菌的抗菌药敏模式。
J Antimicrob Chemother. 2001 Jul;48(1):53-62. doi: 10.1093/jac/48.1.53.
7
[Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].达托霉素对革兰氏阳性微生物的体外比较活性：西班牙哨兵监测项目（2002 - 2006年）
Enferm Infecc Microbiol Clin. 2008 Oct;26(8):489-94.
8
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.达托霉素、利奈唑胺和奎奴普丁-达福普汀对包括万古霉素中介金黄色葡萄球菌和万古霉素耐药粪肠球菌在内的葡萄球菌和肠球菌挑战组的体外活性。
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
9
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.达托霉素、利奈唑胺和奎奴普丁/达福普汀对某大型癌症中心革兰氏阳性菌分离株的体外活性比较
Diagn Microbiol Infect Dis. 2005 Jul;52(3):255-9. doi: 10.1016/j.diagmicrobio.2005.02.015.
10
Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.喹奴普丁/达福普汀对肠球菌属的体外活性比较
J Antimicrob Chemother. 1997 May;39 Suppl A:41-6. doi: 10.1093/jac/39.suppl_1.41.
引用本文的文献
1
Antibiotic resistance, efflux pump genes and virulence determinants in Enterococcus spp. from surface water systems.地表水系统中肠球菌属的抗生素耐药性、外排泵基因及毒力决定因素
Environ Sci Pollut Res Int. 2016 Nov;23(21):21501-21510. doi: 10.1007/s11356-016-7369-7. Epub 2016 Aug 11.
2
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述：聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
3
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀：用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
4
Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.欧洲引起感染的肠球菌的抗菌药敏模式。欧洲耐万古霉素肠球菌研究小组。
Antimicrob Agents Chemother. 1999 Oct;43(10):2542-6. doi: 10.1128/AAC.43.10.2542.
本文引用的文献
1
The chemistry and biological profile of trovafloxacin.曲伐沙星的化学和生物学特性。
J Antimicrob Chemother. 1997 Jun;39 Suppl B:1-14. doi: 10.1093/jac/39.suppl_2.1.
2
Enterococci acquire new kinds of resistance.肠球菌获得了新的耐药类型。
Clin Infect Dis. 1997 Jan;24 Suppl 1:S80-4. doi: 10.1093/clinids/24.supplement_1.s80.
3
In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.新型8-甲氧基喹诺酮BAY 12-8039的体外活性
Chemotherapy. 1996 Nov-Dec;42(6):410-25. doi: 10.1159/000239474.
4
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素，对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
5
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.两种新型氟化恶唑烷酮U-100592和U-100766的体外抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
6
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.新型半合成四环素类——甘氨酰环素的体外和体内抗菌活性
Antimicrob Agents Chemother. 1993 Nov;37(11):2270-7. doi: 10.1128/AAC.37.11.2270.
7
Risk factors for acquiring ampicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital.加拿大一家三级护理医院中获得耐氨苄西林肠球菌的危险因素及临床结局
J Clin Microbiol. 1994 Nov;32(11):2671-6. doi: 10.1128/jcm.32.11.2671-2676.1994.
8
Dissociated resistance among fluoroquinolones.氟喹诺酮类药物之间的解离抗性。
Antimicrob Agents Chemother. 1994 Sep;38(9):2095-100. doi: 10.1128/AAC.38.9.2095.
9
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.临床分离株中出现的多重耐药肠球菌。一、美国97个医学中心监测研究的患病率数据。肠球菌研究组。
Diagn Microbiol Infect Dis. 1995 Feb;21(2):85-93. doi: 10.1016/0732-8893(94)00147-o.
10
An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome.
Medicine (Baltimore). 1995 Jul;74(4):191-200. doi: 10.1097/00005792-199507000-00003.
Zotero 插件